



**5th INTERNATIONAL CONFERENCE
ACUTE MYELOID LEUKEMIA “MOLECULAR AND TRANSLATIONAL”:
ADVANCES IN BIOLOGY AND TREATMENT
Estoril, Portugal
October 24-26, 2019**

Chairs: Bob Löwenberg, Hartmut Döhner, Martin Tallman

Thursday, October 24, 2019

08:30–08:40 Welcome
Bob Löwenberg (Rotterdam), Hartmut Döhner (Ulm), Martin Tallman (New York)

SESSION I - LEUKEMIA STEM CELLS

Chairs: TBA

08:40-08:55 Stem cells in human AML Ravindra Majeti (Stanford)
08:55-09:00 *Discussion*

09:00-09:15 Molecular control and therapy resistance of AML stem cells Andreas Trumpp (Heidelberg)
09:15-09:20 *Discussion*

09:20-09:35 Therapeutic targeting AML stem cells TBA
09:35-09:40 *Discussion*

09:40-10:10 *Panel discussion*

10:10-10:40 Coffee Break

SESSION II - CLONAL HEMATOPOIESIS AND CLONAL DIVERSITY

Chairs: TBA

10:40-10:55 The biological and clinical impact of clonal hematopoiesis Siddharta Jaiswal (Stanford)*
10:55-11:00 *Discussion*

11:00-11:15 Clonal hematopoiesis: predicting development of AML Liran Shlush (Rehovot)
11:15-11:20 *Discussion*

11:20-11:35 DNMT3A and mechanisms of regulating clonal diversity in bone marrow Peggy Goodell (Houston)
11:35-11:40 *Discussion*

11:40-12:10 *Panel discussion*

12:10-13:50 *Lunch*

12:40-13:40 3 Simultaneous Meet the Expert Sessions

1. Treatment of molecular subsets of AML Eytan Stein (New York)
2. Introducing novel drugs in our current treatment algorithm of AML Andrew Wei (Melbourne)
3. Taking advantage of MRD assessment in clinical practice Gert Ossenkoppele (Amsterdam)

12:40-13:40 Time slot for a satellite symposium

SESSION III - GENETICS AND EPIGENETICS

Chairs: TBA

- 13:50-14:05 The AML genome(s) and epigenome(s) Tim Ley (Saint-Louis)
14:05-14:10 *Discussion*
- 14:10-14:25 Enhancer and 3D genome remodelling Brian Huntly (Cambridge)
in the induction and maintenance of leukemia
14:25-14:30 *Discussion*
- 14:30-14:45 Molecular breakdown of EVI1-AML Ruud Delwel (Rotterdam)
14:45-14:50 *Discussion*
- 14:50-15:05 Mutational Cooperativity and AML Pathogenesis Ross Levine (New York)
15:05-15:10 *Discussion*
- 15:10 -15:25 Role of MBD4 in AML development Ian Majewski (Melbourne)
15:25-15:30 *Discussion*
- 15:30-16:00 *Panel discussion*

16:00-16:30 *Coffee break*

SESSION IV - PRELEUKEMIC CONDITIONS

Chairs: TBA

- 16:30-16:45 Molecular mechanisms driving malignant Ivo Touw (Rotterdam)
transformation of severe congenital neutropenia
16:45-16:50 *Discussion*
- 16:50-17:05 Inherited bone marrow failure Jean Soulier (Paris)
as a preleukemic condition
17:05-17:10 *Discussion*
- 17:10-17:25 Marrow Failure and AML Development Akiko Shimamura (Boston)
17:25-17:30 *Discussion*
- 17:30-17:45 Mechanisms of progression of the MPNs to AML John Crispino (Chicago)
17:45-17:50 *Discussion*

17:50-18:05	Recognition of patients with germline susceptibility to myeloid malignancies	Lucy Godley (Chicago)
18:05-18:10	<i>Discussion</i>	
18:10-18:40	<i>Panel discussion</i>	
18:40-20:15	On-Site Get-Together and Poster Walk (Cocktails and stand up buffet dinner for all)	

Friday, October 25, 2019

08:00-09:00 Time slot for a satellite symposium

SESSION V: MOLECULAR THERAPEUTICS I

Chairs: TBA

09:15-09:30	CRISPR and drug screens for therapeutics of AML	Kimberley Stegmaier (Boston)
09:30-09:35	<i>Discussion</i>	
09:35-09:50	Targeting Chromatin Complexes in AML	Scott Armstrong (Boston)
09:50-09:55	<i>Discussion</i>	
09:55-10:10	Bcl-2/Mcl-1 targeting (translational aspects)	Andrew Roberts (Melbourne)
10:10-10:15	<i>Discussion</i>	
10:15-10:30	Targeting RUNX1	Guy Sauvageau (Montreal)
10:30-10:35	<i>Discussion</i>	
10:35-11:05	<i>Panel discussion</i>	
11:05-11:35	<i>Coffee break</i>	

SESSION VI: BIOLOGY OF MINIMAL RESIDUAL DISEASE

Chairs: TBA

11:35-11:50	Molecular MRD	Peter Valk (Rotterdam)
11:50-11:55	<i>Discussion</i>	
11:55-12:10	Single Cell MRD in AML	Paresh Vyas (Oxford)
12:10-12:15	<i>Discussion</i>	
12:15-12:30	Flow Cytometric MRD	Jacqueline Cloos (Amsterdam)
12:30-12:35	<i>Discussion</i>	
12:35-13:05	<i>Panel discussion</i>	
13:05-14:45	<i>Lunch</i>	

13:35-14:35 3 Simultaneous Meet the Expert Sessions

- | | |
|---|--------------------------|
| 1. Integrating molecular diagnostics in clinical management | Peter Valk (Rotterdam) |
| 2. Treatment of the older patient with AML | Hartmut Döhner (Ulm) |
| 3. Trial design | Bob Löweberg (Rotterdam) |

13:35-14:35 Time slot for a satellite symposium

SESSION VII: IMMUNOTHERAPEUTIC TARGETING

Chairs: TBA

- | | | |
|--------------------|--|-----------------------------|
| 14:45-15:00 | CAR T cells targeting CD44v6 | Monica Casucci (Milan) |
| 15:00-15:05 | <i>Discussion</i> | |
| 15:05-15:20 | Anti 123 bispecific mAb | John DiPersio (Saint-Louis) |
| 15:20-15:25 | <i>Discussion</i> | |
| 15:25-15:40 | TBA | |
| 15:40-15:45 | <i>Discussion</i> | |
| 15:45-16:00 | Immune targeting of tumor necrosis factor receptors/CD70 in leukemia | Adrian Ochsenbein (Bern) |
| 16:00-16:05 | <i>Discussion</i> | |
| 16:05-16:35 | <i>Panel discussion</i> | |
| 16:35-17:05 | <i>Coffee Break</i> | |

SESSION VIII: MOLECULAR THERAPEUTICS II

Chairs: TBA

- | | | |
|-------------|--|-------------------------------|
| 17:05-17:20 | FLT3 inhibition | Alexander Perl (Philadelphia) |
| 17:20-17:25 | <i>Discussion</i> | |
| 17:25-17:40 | Effects of FLT3-ITD on Myeloid Differentiation | Martin Carroll (Philadelphia) |
| 17:40-17:45 | <i>Discussion</i> | |
| 17:45-18:00 | Inhibition of FLT3-ITD to enhance GVL effects | Robert Zeiser (Freiburg) |
| 18:00-18:05 | <i>Discussion</i> | |
| 18:05-18:20 | FLT3 inhibitor therapeutic combinations | Cathy Smith (San Francisco) |
| 18:20-18:25 | <i>Discussion</i> | |
| 18:25-18:55 | <i>Panel discussion</i> | |

19:15-20:15 Time slot for a satellite symposium

Saturday, October 26, 2019

08:00-09:00 **Time slot for a satellite symposium**

SESSION IX: MOLECULAR THERAPEUTICS III

Chairs: TBA

09:15-09:30	MDM2 P53 targeting	Marina Konopleva (Houston)
09:30-09:35	<i>Discussion</i>	
09:35-09:50	Clinical developments of Bcl-2/Mcl-1 targeting	Andrew Wei (Melbourne)
09:50-09:55	<i>Discussion</i>	
09:55-10:10	Targeting dihydroorotate dehydrogenase	David Scadden (Boston)
10:10-10:15	<i>Discussion</i>	
10:15-10:30	Targeting IDH1/IDH2	Eytan Stein (New-York)
10:30-10:35	<i>Discussion</i>	
10:35-11:05	<i>Panel discussion</i>	
11:05-11:15	<i>Closing remarks</i>	

MEETING CLOSURE

**pending confirmation*